FDA Approved: ARIKAYCE — Supplemental Application (Insmed Incorporated)

View source ↗

Summary

FDA approved a supplemental application for ARIKAYCE (amikacin liposome inhalation suspension) from Insmed Incorporated. This action updates ARIKAYCE's labeling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycobacterium Avium Complex Infection
• Non-tuberculous Mycobacterial Lung Disease

Drugs mentioned

• Arikayce (amikacin liposome inhalation suspension)

Snippet

SUPPL AP for ARIKAYCE (AMIKACIN)